Drugs.com - Clinical Trials

Teva Celiac Disease Candidate TEV-53408 Granted Fast Track Designation by US FDA

TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA) today announced that the US Food and Drug Administration (FDA) granted Fast Track designation for investigational TEV-53408, an anti-IL-15...

May 30, 2025 - 04:10
 0
Teva Celiac Disease Candidate TEV-53408 Granted Fast Track Designation by US FDA
TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA) today announced that the US Food and Drug Administration (FDA) granted Fast Track designation for investigational TEV-53408, an anti-IL-15...
Read More

Tags:

Previous Article

Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for...

Next Article

Toyota Plans To Get Out Of The EV & PHEV Slow Lane In The US

Related Posts

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

Itepekimab Met Primary Endpoint in One of Two Chronic O...

May 31, 2025  0

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for...

May 28, 2025  0

Apnimed Announces Positive Topline Results in the First Landmark Phase 3 Clinical Trial of AD109, an Investigational Once-Daily Oral Pill for Obstructive Sleep Apnea

Apnimed Announces Positive Topline Results in the First...

May 20, 2025  0